Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
| ▸ | ACP1 | P24666 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486496 | 0.86 | KDM4E (0.70) | NQO1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL14500755 | 0.82 | NPC1 (0.59) | NQO1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL30228591 | 0.81 | NPC1 (0.58) | NQO1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL5547120 | 0.81 | NPC1 (0.54) | NQO1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL5682765 | 0.80 | KDM4E (0.66) | NQO1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL30228475 | 0.80 | KDM4E (0.66) | NQO1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL21282186 | 0.80 | NQO1 (0.57) | NQO1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL2162844 | 0.79 | APP (0.57) | NQO1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL2604870 | 0.79 | NQO1 (0.53) | NQO1KDM4ENPC1RAB9AHPGDS | |
| SCHEMBL28992132 | 0.79 | PDGFRB (0.57) | NQO1KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-11-24 | — | — | US | disclosed |
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-09-29 | — | — | US | disclosed |
| US-9433618-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-08-04 | — | — | US | disclosed |
| US-9364481-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9315462-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160067254-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-03-10 | — | — | US | disclosed |
| EP-2977050-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | Nivalis Therapeutics, Inc. (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9221810-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-8921562-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140329821-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8785643-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2651223-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261123-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2013-10-03 | — | — | US | disclosed |
| EP-2624695-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| CN-103200820-A | Novel substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS LLC | 2013-07-10 | — | — | CN | disclosed |
| WO-2012083165-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012048181-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | NQO1 6/4885KDM4E 2042/4885ALDH1A1 290/4885 |
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | NQO1 13/4885KDM4E 1484/4885ALDH1A1 329/4885 |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | NQO1 6/4885KDM4E 2042/4885ALDH1A1 290/4885 |
| US-20140329821-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | NQO1 13/4885KDM4E 1484/4885ALDH1A1 329/4885 |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | NQO1 6/4885KDM4E 2042/4885ALDH1A1 290/4885 |
| US-20160067254-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | NQO1 13/4885KDM4E 1484/4885ALDH1A1 329/4885 |
| US-20130261123-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | NQO1 13/4885KDM4E 1484/4885ALDH1A1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.